New Somatostatin-derived substances for the treatment of neuropathic pain and related disorders
Neuropathic pain is rather resistant
to conventional analgesics. Therefore, different approaches must be taken to treat neuropathic pain. One possibility is the use of agents acting at the level of the sensory nerve terminals themselves to inhibit the release of these pro-inflammatory/pronociceptive sensory neuropeptides. Such agents may form the basis for the development of a new group of anti-inflammatory and analgesic drugs. In this invention Somatostatin-derived substances were developed that can inhibit inflammation without accompanying endocrine side effects. Furthermore they exhibit satisfactory half life and bioavailability, especially after oral administration.
Further Information: PDF
Bayerische Patentallianz GmbH
Phone: +49 89 5480177-0
Contact
Peer Biskup
Media Contact
All latest news from the category: Technology Offerings
Newest articles
A universal framework for spatial biology
SpatialData is a freely accessible tool to unify and integrate data from different omics technologies accounting for spatial information, which can provide holistic insights into health and disease. Biological processes…
How complex biological processes arise
A $20 million grant from the U.S. National Science Foundation (NSF) will support the establishment and operation of the National Synthesis Center for Emergence in the Molecular and Cellular Sciences (NCEMS) at…
Airborne single-photon lidar system achieves high-resolution 3D imaging
Compact, low-power system opens doors for photon-efficient drone and satellite-based environmental monitoring and mapping. Researchers have developed a compact and lightweight single-photon airborne lidar system that can acquire high-resolution 3D…
